Intellectus Partners LLC Purchases 32,053 Shares of Affimed (NASDAQ:AFMD)

Intellectus Partners LLC grew its position in Affimed (NASDAQ:AFMD) by 34.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 126,414 shares of the biopharmaceutical company’s stock after purchasing an additional 32,053 shares during the quarter. Intellectus Partners LLC owned approximately 0.79% of Affimed worth $150,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Point72 Asset Management L.P. boosted its stake in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the last quarter. FMR LLC boosted its stake in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Affimed in the 3rd quarter valued at $44,000. 30.82% of the stock is owned by institutional investors.

Affimed Trading Up 0.2 %

Affimed stock opened at $0.99 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 12-month low of $0.92 and a 12-month high of $8.95. The firm’s fifty day moving average is $1.09 and its 200 day moving average is $2.44.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research note on Tuesday, December 10th. Wells Fargo & Company dropped their target price on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. Finally, Stifel Nicolaus dropped their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Affimed has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.